Access in all areas? A round up of developments in market access and HTA: part 5 by Alice Beattie, Francisco Olivenca, Catrin Treharne, Sreeram V Ramagopalan

Why is the market design for innovative pharmaceuticals not well understood? by Francisco Olivenca, Jose Diaz, Sreeram V Ramagopalan, Louis P Garrison Jr

The Mycobacteriophage Ms6 LysB <i>N</i>-Terminus Displays Peptidoglycan Binding Affinity by Adriano M. Gigante, Francisco Olivença, Maria João Catalão, Paula Leandro, José Moniz-Pereira, Sérgio R. Filipe, Madalena Pimentel

Get full text

Identification of drivers of mycobacterial resistance to peptidoglycan synthesis inhibitors by Francisco Olivença, Cláudia Ferreira, Alexandra Nunes, Alexandra Nunes, Cátia Silveiro, Madalena Pimentel, João Paulo Gomes, João Paulo Gomes, Maria João Catalão

Get full text

CRISPRi-mediated characterization of novel anti-tuberculosis targets: Mycobacterial peptidoglycan modifications promote beta-lactam resistance and intracellular survival by Cátia Silveiro, Mariana Marques, Francisco Olivença, David Pires, David Pires, Diana Mortinho, Alexandra Nunes, Alexandra Nunes, Madalena Pimentel, Elsa Anes, Maria João Catalão

Get full text